Sandoz has claimed the first FDA approvals for biosimilars of Amgen’s blockbuster bone disease therapy denosumab, but has not said when it plans to launch them onto the US
As society globally faces a growing elderly population, age-related conditions such as osteoporosis are coming to the forefront as critical issues. More emphasis needs to be placed on secon
US biotech Rani Therapeutics has shown that its oral formulation of a drug for osteoporosis that currently has to be delivered by injection worked as hoped in a first-in-h
Novartis' soon-to-be-divested Sandoz unit has filed its proposed biosimilar of Amgen's osteoporosis therapy Prolia/Xgeva with the FDA, saying it is "among the first" to fi
Boehringer Ingelheim says it may have found the first therapy for diabetic macular ischaemia (DMI), a common and irreversible complication of the eye in people with diabet
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.